Mirae Asset Global Etfs Holdings Ltd. Moon Lake Immunotherapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $56.2 Billion
- Q3 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 11,954 shares of MLTX stock, worth $152,652. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,954
Previous 15,752
24.11%
Holding current value
$152,652
Previous $743,000
88.56%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding MLTX
# of Institutions
177Shares Held
38.5MCall Options Held
4.13MPut Options Held
1.51M-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.99MShares$25.5 Million2.28% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.7MShares$21.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $472M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...